Foghorn Therapeutics Inc share price logo

Foghorn Therapeutics Inc

NASDAQ: FHTX

Small Cap

$4.62

-0.05

(-1.18%)

as on

Foghorn Therapeutics Inc Stock Performance

as on May 6, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $4.64
    $4.86
    downward going graph

    -0.43%

    Downside

    5.19%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.27
    $6.95
    downward going graph

    29.22%

    Downside

    50.43%

    Upside

    downward going graph

Foghorn Therapeutics Inc share price movements today

Previous Close
$4.68
Open
$4.72
Volume
176.3K
Day's Low - High
$4.64 - $4.86
52 Week Low - High
$3.27 - $6.95

Foghorn Therapeutics Inc Historical Returns

1 Month Return
-4.1 %
3 Month Return
-17.61 %
1 Year Return
+ 17.59 %
3 Year Return
-22.64 %
5 Year Return
-54.07 %

Foghorn Therapeutics Inc Stock Fundamentals & Key Indicators

Check Foghorn Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$279.4M

EPS (TTM)

-1.15

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-78.8M

Revenue (TTM)

30.9M

Profit Margin

-240.33%

Return On Equity TTM

-470.38%

Foghorn Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Foghorn Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$279.4M-54.07%NA-240.33%
BUY$39.8B125.53%74.6712.55%
BUY$109.3B101.66%27.732.94%
NA$33.0BNA118.865.37%
BUY$73.5B42.22%17.1229.65%

Stock Returns calculator for Foghorn Therapeutics Inc Stock including INR - Dollar returns

The Foghorn Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Foghorn Therapeutics Inc investment value today

Current value as on today

₹1,31,208

Returns

₹31,208

(+31.21%)

Returns from Foghorn Therapeutics Inc Stock

₹16,080 (+16.08%)

Dollar Impact

₹15,128 (+15.13%)

Analyst Recommendation on Foghorn Therapeutics Inc Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for Foghorn Therapeutics Inc. Average target price of $11.44

Foghorn Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Foghorn Therapeutics Inc.

What analysts predicted

59.62%UPSIDE

Target Price

$11.44

Current Price

$4.62

Analyzed by

11 Analysts

Target

$11.44

Foghorn Therapeutics Inc target price $11.44, a slight upside of 59.62% compared to current price of $4.62. According to 11 analysts rating.

Foghorn Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Foghorn Therapeutics Inc Stock has increased by 240% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:240% versus previous 30 day period

Foghorn Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
17
5
5
6
7
2
5
7
8
9
Gross Profit
-8
4
5
6
7
2
5
6
-11
8
Operating Income
-17
-25
-28
-26
-23
-24
-22
-21
-18
-19
EBITDA
-16
-24
-27
-23
-23
-23
-22
-17
-14
-18
Interest Expense
-
2
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-13
-22
-25
-22
-19
-19
-18
-17
-15
-21
Income Tax Expense
0
1
0
-
0
0
-
-
-
-
Net Income
-14
-24
-25
-22
-19
-19
-18
-17
-15
-21
Net Profit Margin
-82.07%
-417.85%
-495.37%
-333.61%
-244.90%
-682.88%
-316.43%
-237.34%
-194.39%
-234.28%

Foghorn Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
1
19
34
22
30
Gross Profit
0
-1
-57
1
19
34
22
27
Operating Income
-26
-51
-68
-100
-117
-107
-102
-82
EBITDA
-25
-48
-67
-96
-113
-104
-97
-78
Interest Expense
0
0
0
1
11
-
-
-
Depreciation
0
0
1
3
3
3
3
3
Income Before Tax
-26
-51
-68
-101
-108
-94
-86
-74
Income Tax Expense
0
0
0
1
0
4
-
-
Net Income
-26
-51
-68
-101
-108
-98
-86
-74
Net Profit Margin
0.00%
0.00%
-16000.00%
-7681.58%
-566.23%
-288.17%
-383.24%
-240.33%

Foghorn Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-24
-25
-22
-19
-19
-18
-17
-15
-21
Operating Cash Flow
-27
-29
-25
-21
-24
-23
-21
-18
-22
Investing Cash Flow
37
27
-17
-61
22
29
33
35
13
Financing Cash Flow
0
1
103
1
0
0
0
0
0
Change in Cash
10
-1
59
-81
-2
5
12
16
-8

Foghorn Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-51
-68
-101
-108
-98
-86
-74
Operating Cash Flow
-46
-31
-50
193
-118
-100
-86
Investing Cash Flow
0
-108
36
-244
144
-29
112
Financing Cash Flow
23
217
22
1
1
105
1
Change in Cash
-23
77
8
-48
28
-24
26

Global Institutional Holdings in Foghorn Therapeutics Inc

Funds
Holdings
Birchview Capital, LP
0.48%
Geode Capital Management, LLC
1.38%
Deerfield Management Co
6.22%
Bvf Inc
9.03%
Ameriprise Financial Inc
0.2%

Insights on Foghorn Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 5 quarters, 2.85M → 9.24M (in $), with an average increase of 23.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, FOGHORN THERAPEUTICS INC has experienced a drawdown of -22.6%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 15.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 27.0% return, outperforming this stock by 9.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -15.84M → -21.66M (in $), with an average decrease of 36.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, FHTX stock has moved down by -1.7%

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
OrganisationFoghorn Therapeutics Inc
Headquarters99 Coolidge Avenue, Watertown, MA, United States, 02472
IndustryBiotechnology
CEOMr. Adrian H. B. Gottschalk
E-voting on sharesClick here to vote

Key Management of Foghorn Therapeutics Inc

Name

Title

Ms. Karin Hellsvik

Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations

Dr. Alfonso Quintas Cardama M.D.

Chief Medical Officer

Mr. Adrian H. B. Gottschalk

President, CEO & Director

Dr. Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Mr. Ryan D. Maynard

Chief Financial Officer

Mr. Saurabh Sewak Ph.D.

Vice President of Corporate Development

Mr. Carlos Costa

Chief People Officer

Dr. Anna Rivkin Ph.D.

Chief Business Officer

Dr. Steven F. Bellon Ph.D.

Chief Scientific Officer

Mr. Michael J. LaCascia J.D.

Chief Legal Officer

FAQs

What is Foghorn Therapeutics Inc share price today?

Foghorn Therapeutics Inc share price today is $4.62 as on at the close of the market. Foghorn Therapeutics Inc share today touched a day high of $4.86 and a low of $4.64.

What is the 52 week high and 52 week low for Foghorn Therapeutics Inc share?

Foghorn Therapeutics Inc share touched a 52 week high of $6.95 on and a 52 week low of $3.27 on . Foghorn Therapeutics Inc stock price today i.e. is closed at $4.62,which is 33.53% down from its 52 week high and 41.28% up from its 52 week low.

What is Foghorn Therapeutics Inc's market capitalisation today?

Foghorn Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Foghorn Therapeutics Inc Stock (FHTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Foghorn Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Foghorn Therapeutics Inc Shares that will get you 0.3247 shares as per Foghorn Therapeutics Inc share price of $4.62 per share as on May 6, 2026 at 1:29 am IST.

What is the minimum amount required to buy Foghorn Therapeutics Inc Stock (FHTX) from India?

Indian investors can start investing in Foghorn Therapeutics Inc (FHTX) shares with as little as ₹95.28 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.80 in Foghorn Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Foghorn Therapeutics Inc share’s latest price of $4.62 as on May 6, 2026 at 1:29 am IST, you will get 2.1645 shares of Foghorn Therapeutics Inc. Learn more about fractional shares .

What are the returns that Foghorn Therapeutics Inc has given to Indian investors in the last 5 years?

Foghorn Therapeutics Inc stock has given -54.07% share price returns and 28.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?